FDA Approves First Treatment for Adult Onset Still’s Disease |
Clinical News
eMediNexus Coverage from: 
FDA Approves First Treatment for Adult Onset Still’s Disease

0 Read Comments                

The U.S. Food and Drug Administration has granted approval for canakinumab injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD).

The drug was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older. It blocks the effects of interleukin-1 (IL-1) and suppresses inflammation in patients with this autoinflammatory disorder… (FDA, June 16, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now